Myasthenia Gravis — Research Summary
Printed from RareWays (rareways.com.au) on 10 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
From Limited Samples to Mechanistic Insights: Exploratory Identification and Functional Validation of a hsa_circ_0062400/hsa_circ_0002397-miR-338-3p-NRP1 Axis in Myasthenia Gravis
Chen Z et al. — Endocr Metab Immune Disord Drug Targets (18 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41863473/
- 2.
Bridging the gap between patient and physician perspectives on management of generalized myasthenia gravis: a Delphi consensus study
Chan A et al. — Orphanet J Rare Dis (20 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41862942/
- 3.
The Effect of Thymectomy on the Incidence of Extrathymic Cancers and Autoimmune Diseases in Patients With Non-Thymomatous Myasthenia Gravis
Khateb M et al. — Muscle Nerve (20 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41862279/
- 4.
Burden of glucocorticoid use in commercially insured adults with generalized myasthenia gravis in the United States: A retrospective claims-based analysis
Silvestri NJ et al. — Medicine (Baltimore) (20 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41861184/
- 5.
Hsa_circ_0000313/miR-1224-3p/MKNK2 Axis Modulates CD4+ T Cells by Activating p38 MAPK Signaling in Myasthenia Gravis
Li Y et al. — Mediators Inflamm (1 January 2026)
https://pubmed.ncbi.nlm.nih.gov/41860006/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Myasthenia Gravis
Myasthenia gravis is a chronic autoimmune condition in which the immune system attacks the connection between nerves and muscles, causing muscle weakness that worsens with activity. It affects approximately 5,000-7,000 Australians. A rapidly expanding range of treatments, including new targeted therapies, can now achieve good symptom control for many patients.
Most Recent Research
Common Questions
What is Myasthenia Gravis?
Myasthenia gravis is a chronic autoimmune condition in which the immune system attacks the connection between nerves and muscles, causing muscle weakness that worsens with activity. It affects approximately 5,000-7,000 Australians. A rapidly expanding range of treatments, including new targeted therapies, can now achieve good symptom control for many patients.
How many clinical trials are available for Myasthenia Gravis?
RareWays currently indexes 22 clinical trials for Myasthenia Gravis, of which 8 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Myasthenia Gravis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Myasthenia Gravis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.